Gastrointestinal stromal tumor | Tumor

Many Survivors of GISTs, a Rare Cancer, May Experience Cancer-Related Cognitive Impairments After Treatment

October 5th 2022

Nearly two thirds of patients with GISTs — a rare type of cancer that often begins in the digestive system — indicated that their overall quality of life after treatment had been affected by cancer-related cognitive impairments, also referred to as “chemo brain,” according to analysis of survey data.

GIST Location Predicts Tumor Mutation Profile and Drug Sensitivity

August 13th 2021

The location of gastrointestinal stromal tumors in the stomach predicts the mutation profile and drug sensitivity, which can provide direction for treatment decisions and selective genomic testing.

Drug-Resistant GIST: Identifying Patients and Finding Solutions

July 14th 2021

Gastrointestinal stromal tumors that are SDH deficient are less likely to respond to TKI treatment. A researcher discusses the exploration of a new drug that can work in this patient population.

Rare Cancers: Collaboration Moves the Field Forward

July 13th 2021

Patients, clinicians and researchers should work together to find new therapies for rare cancers, one expert says.

How Do Clinical Trials Work? Cancer Expert Explains It All

July 1st 2021

Will patients be given a placebo? Are clinical trials safe? An expert answers these questions and more.

When Treatment Options Run Out, Consider a Higher Drug Dose in GIST

June 29th 2021

In patients with advanced gastrointestinal stromal tumors, a dose escalation of Qinlock after recommended treatment with the agent may be the best next step, answering for the lack of a next approved agent after Qinlock.

Early Evidence Shows Gleevec-Xpovio Combo May Benefit Patients With Rare Form of Advanced Gastrointestinal Cancer

June 25th 2021

The combination of Gleevec and Xpovio demonstrated some promising results in a small group of patients with a rare form of advanced gastrointestinal cancer whose disease had failed to respond to prior first-line treatment with Gleevec.

Dose Escalation of Qinlock Shows Benefit in Patients With Advanced GIST

June 22nd 2021

The findings open up the door for a fourth-line treatment option in patients with advanced gastrointestinal stromal tumors with disease progression.

Novel Drug Significantly Improves Survival in Rare Gastrointestinal Cancer

June 9th 2021

Treatment with the study drug was associated with a doubling of a survival outcome in patients with advanced gastrointestinal stromal tumor, compared to placebo.

Higher Dose of Qinlock Improves Survival in Patients with Heavily Pretreated Advanced GIST

June 7th 2021

Twice-daily treatment with Qinlock following disease progression after treatment with fourth-line therapy in patients with advanced gastrointestinal stromal tumor was associated with extended survival outcomes.

Ayvakit Shows Promise for Patients with Gastrointestinal Stomach Tumors With Specific Mutation

April 16th 2021

Ayvakit demonstrated more durable survival outcomes in patients with unresectable/metastatic platelet-derived growth factor receptor A D842V-mutant gastrointestinal stromal tumors than tyrosine kinase inhibitors.

Cancer Sometimes Does Not See Age

March 27th 2021

It is difficult for anyone to receive a cancer diagnosis, but when someone who is younger than average finds out they have gastrointestinal cancer, they may face other challenges.

Getting the Gist on GIST

March 24th 2021

In a recent interview with CURE®, an expert from Fox Chase Cancer Center discussed gastrointestinal stromal tumors (GIST) and addressed a multitude of topics including common symptoms associated with the disease, and potential future therapies that may be beneficial for patients.

Investigational Combo Therapy Offers ‘High Hopes’ in Treating Rare Gastrointestinal Cancer

March 23rd 2021

Results of a preliminary clinical trial show that MK-1775 — an investigational therapy — as a single agent, or in combination with Ayvakit, may be effective in the treatment of gastrointestinal stromal tumors. However, one of the study’s authors notes that further research is needed to determine a benefit in patients.

Advanced-Stage Rare Type of Gastrointestinal Cancer More Common in Men, Associated with ‘Excellent’ 5-Year Survival Rates

January 19th 2021

The data in the study presented at the ASCO Gastrointestinal Cancers Symposium demonstrated that while rare, stage 4 gastrointestinal stromal tumors often spread to the liver.

Novel Artificial Intelligence Tool May Help Patients with Cancer Find, Understand Clinical Trials

January 18th 2021

A group of patients with gastrointestinal cancers reported that a novel artificial intelligence-based search tool made it easier for them to find and understand cancer clinical trials. The tool, according to study authors, would not only help with trial accrual, but could also help improve trial diversity.

FDA Approves Qinlock for Patients with Pretreated, Advanced GIST

May 16th 2020

The targeted drug Qinlock, which interferes with the activity of proteins that drive gastrointestinal stromal tumor, has been approved by the Food and Drug Administration for patients with advanced disease that has progressed despite treatment with other kinase inhibitors.

What You Need to Know About the FDA's Approval of Avyakit for GIST Subgroup

January 13th 2020

Patients with gastrointestinal stromal tumors have a new targeted therapy that looks to tackle secondary mutations after it showed a strong response rate in the clinic.

FDA Approves Ayvakit for the Treatment of Certain Patients with Gastrointestinal Stromal Tumor

January 10th 2020

The Food and Drug Administration approved Ayvakit for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor who exhibited a platelet-derived growth factor receptor alpha exon 18 mutation.

Hitting a Target in Gastrointestinal Stromal Tumors

August 2nd 2017

How zeroing in on the mutation in gastrointestinal stromal tumors is adding years to patients’ lives

Collaboration Lays the Groundwork for Breakthroughs in GIST

January 29th 2017

The Life Raft Group, a patient advocacy organization, is teaming up with research organizations to hopefully find the next wave of treatment for patients with gastrointestinal stromal tumors.

Gastrointestinal Stromal Tumors Already Proving to Be Treatable With Targeted Therapies

March 23rd 2016

Identified only a decade-and-a-half ago, GIST is already treatable with several targeted therapies, and scientists are researching more.

Side Effects Associated With Other Treatments for GIST

October 22nd 2015

Side Effects Associated With Gleevec for GIST

October 22nd 2015

Treating GIST

October 22nd 2015

What Is GIST?

October 22nd 2015

Part VI: How GIST and I Became Acquainted

August 25th 2015

Moving back into the light.

Part V: How GIST and I Became Acquainted

July 23rd 2015

The hospital agreed to release me back into the wild.

Part IV: How GIST and I Became Acquainted

July 7th 2015

Is this a hospital or have I stepped on the "wayback machine" with the dial set to 1970?

Part III: How GIST and I Became Acquainted

June 24th 2015

The medical team had reached some conclusions.